Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novo Nordisk restarts phase III development of liraglutide for obesity

June 25, 2010

Takeda announces U.S. launch of ACTOplus met XR

June 25, 2010

OMJPI and Diamyd join to develop diabetes therapy rhGAD65

June 25, 2010

VIA Pharmaceuticals discloses new DGAT inhibitors

June 25, 2010

Kowa Pharmaceuticals America and Lilly launch Livalo in the U.S.

June 23, 2010

Zydus receives permission for phase I trial of ZYOG-1 in India

June 22, 2010

FDA recommends approval of emergency contraceptive ulipristal

June 22, 2010

Roche amends trial protocols for taspoglutide phase III program

June 22, 2010

FDA issues PDUFA action date for Orexigen's Contrave obesity therapy

June 21, 2010

Neurocrine and Boehringer to develop GPR119 agonists for type 2 diabetes

June 21, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...